

Clinical Conundrum of Coronary Artery Disease and Aortic Valve Stenosis

Abdallah El Sabbagh, MD; Rick A. Nishimura, MD

Coronary artery disease (CAD) and severe aortic valve stenosis frequently coexist. CAD is prevalent in >60% of patients undergoing surgical aortic valve replacement (SAVR)¹ and up to 65% of patients undergoing transcatheter aortic valve replacement (TAVR).² This strong association is thought to be due to the common pathophysiology involving low-density lipoprotein-mediated inflammatory response resulting in an accelerated atherosclerotic process and shares similar risk factors including age, smoking, hypertension, and hyperlipidemia.³

Historically, concomitant CAD in patients undergoing SAVR for aortic stenosis was treated by coronary artery bypass grafting (CABG) at the time of SAVR, although there was the presumption of a significantly increased operative risk with the addition of CABG. The rationale for concomitant CABG originates from limited early surgical data in which patients undergoing SAVR with unrevascularized CAD had poorer long-term outcomes compared with those that had CABG.^{4,5} This rationale has now been reinforced by a recent study showing that coronary artery revascularization at the time of aortic valve replacement was associated with improved long-term survival without affecting operative risk. The survival benefit, however, was seen mostly in the group that received a left internal mammary artery to the left anterior descending artery, whereas this benefit was not seen in those that had bypass grafting of the circumflex and right coronary arteries only.⁶ Importantly, there has never been a randomized controlled trial of SAVR with versus without CABG. The current American College of Cardiology and American Heart Association valve guidelines give a class IIa recommendation

for revascularization of >70% luminal reduction in major coronary arteries or >50% luminal reduction in the left main coronary artery,⁷ based more on opinion than evidence.

The introduction of TAVR has presented a paradigm shift in treating severe aortic valve stenosis. With that came the challenge of optimal management of concomitant CAD. The PARTNER and US CoreValve High Risk Study trials, which led to approval of TAVR by the US Food and Drug Administration, excluded patients with unrevascularized CAD.^{8,9} With further advances in the safety of TAVR, however, attention has turned again to discovering the best approach to treatment. Revascularization with percutaneous coronary intervention (PCI) now, in the early days of TAVR, might be less risky than the addition of CABG was in the early days of SAVR. The potential benefits of revascularization prior to TAVR might include the prevention of myocardial ischemia during periods of hypotension and rapid pacing, especially with increased wall stress, microvascular dysfunction, and impaired coronary blood flow. In contrast, there are risks in performing PCI prior to TAVR. These include periprocedural myocardial infarction; bleeding from antiplatelet agents, especially in patients with atrial fibrillation on anticoagulation; and contrast-induced nephropathy. Again, the long-term benefits of complete revascularization are unclear in this population of patients whose primary problem is the increased afterload from the valve disease.

So far, several observational studies have examined the outcomes of CAD and PCI in patients undergoing TAVR. D'Ascenzo et al published a meta-analysis showing lack of impact of the presence of CAD on mortality in patients undergoing TAVR.² This analysis was limited by the heterogeneous definition of CAD in the multiple studies that were pooled. Other studies looked at the outcomes of PCI and completeness of revascularization prior to TAVR and, for the most part, did not reveal any benefit in terms of lowering rates of mortality or major cardiovascular events.^{10–12}

In this issue of *JAHA*, Paradis et al performed a retrospective analysis of 377 patients who underwent TAVR.¹³ Using quantitative coronary analysis, they calculated a SYNTAX score (SS) and divided patients into 4 groups: no CAD, low SS, intermediate SS, and high SS. They then analyzed their primary outcome, which was a composite of all-cause mortality, stroke, and myocardial infarction at 30 days and 1 year (primary

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

From the Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.

Correspondence to: Rick A. Nishimura, MD, Department of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. E-mail: rnishimura@mayo.edu

J Am Heart Assoc. 2017;6:e005593. DOI: 10.1161/JAHA.117.005593.

© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

outcomes), and found no statistically significant difference between the 4 groups. Interestingly, the patients with no CAD had a higher stroke rate and higher atrial fibrillation burden. They also analyzed echocardiographic data and found no significant improvement in left ventricular ejection fraction after TAVR across all groups. In the second part of the study, they looked closely at the patients who underwent PCI within 6 months and divided them into 2 groups: those with high and low residual SS. They also analyzed those that had CABG and divided them according to their CABG SS. Again, no statistically significant difference was found in the primary outcome at 1 year. The authors concluded that severity of CAD and completeness of revascularization, for either PCI or CABG, did not affect the primary outcome of death, stroke, and myocardial infarction at 30 days and 1 year.

This study is certainly a welcome addition to the literature aimed at unraveling the enigma of managing CAD prior to TAVR; however, some points warrant further discussion:

1. The heterogeneous definition of CAD can add potential confounders to the outcomes. Patients can have stable obstructive lesions found incidentally on pre-TAVR coronary angiogram or unstable lesions with recent myocardial infarction. Such nuances could introduce confounders that can affect outcomes and prognoses.
2. The SS was originally designed to help classify patients with 3-vessel disease or left main disease into PCI or CABG.¹⁴ A cutoff of 50% luminal narrowing was used to define obstructive luminal narrowing. In addition, narrowing in small vessels added to the score. Although it is common practice to surgically bypass lesions with 50% stenosis, this degree of luminal narrowing might not be enough to cause flow limitation during TAVR or even affect long-term outcome. Again, this could present confounders that can attenuate the results of the outcomes and could account for the lack of improvement in the left ventricular ejection fraction observed in this study.
3. The group with no CAD in this study had higher rates of stroke, and this could have driven the higher rates of the primary outcome in that group. Interestingly, this group also had higher prevalence of atrial fibrillation; therefore, these results could have been attributed to periprocedural management of anticoagulation rather than a thrombotic phenomenon.
4. Determining the degree and significance of luminal narrowing in the setting of severe aortic valve stenosis is very challenging. Angina is present in patients with severe aortic stenosis, even in the absence of CAD, and the mechanism is most likely related to failure of increase in coronary blood flow and a shorter diastolic time fraction coupled with an increased demand due to the increased afterload. Consequently, a coronary artery lesion can be a

red herring if angina is present. Alternatively, if a patient presents with severe aortic valve stenosis and concentric hypertrophy—or other causes that increase oxygen demand even more—and has obstructive CAD and no angina, then most likely these coronary lesions are not functionally significant.¹⁵ Given inter- and intraobserver variability with visual assessment of the angiographic lesions, quantitative coronary analysis can assist in more objective measurement of the luminal narrowing. This method, however, can be inaccurate in extremely calcified and tortuous vessels, both of which are common in severe aortic stenosis; intracoronary imaging might be a more favorable diagnostic choice in this circumstance.¹⁶ In addition, functional evaluation of lesions using noninvasive testing or fractional flow reserve is not validated in severe aortic stenosis, given the global ischemia and microvascular dysfunction that is present in these patients.¹⁷ Using the instantaneous wave-free ratio in severe aortic valve stenosis shows promise and is under investigation.¹⁸

History has proven to us on multiple occasions that our approach to revascularizing obstructive lesions has been overenthusiastic. Just like the COURAGE trial showed a lack of benefit over medical therapy in patients with stable CAD¹⁹ and the CARP trial proved that revascularization prior to major elective vascular surgery does not change outcomes,²⁰ we might not be surprised to find that revascularization prior to TAVR does not improve short- and long-term outcomes. The clinical conundrum of managing CAD in patients undergoing TAVR is in need of randomized clinical trials. As the authors alluded to, the results of the ACTIVATION (percutaneous Coronary Intervention prior to transcatheter aortic Valve implantation) trial are closely awaited. In this trial, patients with significant CAD (>70% stenosis in >1 lesion or >50% in vein graft or protected left main coronary artery) will be randomized to PCI or no PCI. Other trials such as PARTNER 2A and SURTAVI will also shed light on the impact of revascularization strategies prior to TAVR. Until then, it would be reasonable to intervene with PCI in patients with proximal left anterior descending or left main CAD prior to TAVR, which has been shown to be feasible without incremental risk compared with TAVR alone,²¹ or in patients who present with severe angina symptoms—but not necessarily apply our “oculostenotic reflex” to all visible lesions seen on coronary angiography.

Disclosures

None.

References

1. Kvidal P, Bergstrom R, Horte LG, Stahle E. Observed and relative survival after aortic valve replacement. *J Am Coll Cardiol*. 2000;35:747–756.

2. D'Ascenzo F, Conrotto F, Giordana F, Moretti C, D'Amico M, Salizzoni S, Omede P, La Torre M, Thomas M, Khawaja Z, Hildick-Smith D, Ussia G, Barbanti M, Tamburino C, Webb J, Schnabel RB, Seiffert M, Wilde S, Treede H, Gasparetto V, Napodano M, Tarantini G, Presbitero P, Mennuni M, Rossi ML, Gasparini M, Biondi Zoccai G, Lupo M, Rinaldi M, Gaita F, Marra S. Mid-term prognostic value of coronary artery disease in patients undergoing transcatheter aortic valve implantation: a meta-analysis of adjusted observational results. *Int J Cardiol.* 2013;168:2528–2532.
3. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. *J Am Coll Cardiol.* 1997;29:630–634.
4. Czer LS, Gray RJ, Stewart ME, De Robertis M, Chau A, Matloff JM. Reduction in sudden late death by concomitant revascularization with aortic valve replacement. *J Thorac Cardiovasc Surg.* 1988;95:390–401.
5. Mullany CJ, Elveback LR, Frye RL, Pluth JR, Edwards WD, Orszulak TA, Nassef LA Jr, Riner RE, Danielson GK. Coronary artery disease and its management: influence on survival in patients undergoing aortic valve replacement. *J Am Coll Cardiol.* 1987;10:66–72.
6. Thalji NM, Suri RM, Daly RC, Greason KL, Dearani JA, Stulak JM, Joyce LD, Burkhardt HM, Pochettino A, Li Z, Frye RL, Schaff HV. The prognostic impact of concomitant coronary artery bypass grafting during aortic valve surgery: implications for revascularization in the transcatheter era. *J Thorac Cardiovasc Surg.* 2015;149:451–460.
7. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM III, Thomas JD, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Creager MA, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Stevenson WG, Yancy CW; Cardiology American College of Association American College of Cardiology/American Heart, and Association American Heart. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Thorac Cardiovasc Surg.* 2014;148:e1–e132.
8. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Buchbinder M, Hermiller J Jr, Kleiman NS, Chetcuti S, Heiser J, Merhi W, Zorn G, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte J, Maini B, Mumtaz M, Chenoweth S, Oh JK; U. S. CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N Engl J Med.* 2014;370:1790–1798.
9. Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, Fontana GP, Dewey TM, Thourani VH, Pichard AD, Fischbein M, Szeto WY, Lim S, Greason KL, Teirstein PS, Malaisrie SC, Douglas PS, Hahn RT, Whisenant B, Zajarias A, Wang D, Akin JJ, Anderson WN, Leon MB; Partner Trial Investigators. Two-year outcomes after transcatheter or surgical aortic-valve replacement. *N Engl J Med.* 2012;366:1686–1695.
10. Abdel-Wahab M, Mostafa AE, Geist V, Stocker B, Gordian K, Merten C, Richardt D, Toelg R, Richardt G. Comparison of outcomes in patients having isolated transcatheter aortic valve implantation versus combined with preprocedural percutaneous coronary intervention. *Am J Cardiol.* 2012;109:581–586.
11. Gasparetto V, Fraccaro C, Tarantini G, Buja P, D'Onofrio A, Yzeiraj E, Pittarello D, Isabella G, Gerosa G, Iliceto S, Napodano M. Safety and effectiveness of a selective strategy for coronary artery revascularization before transcatheter aortic valve implantation. *Catheter Cardiovasc Interv.* 2013;81:376–383.
12. Ussia GP, Barbanti M, Colombo A, Tarantini G, Petronio AS, Etori F, Ramondo A, Santoro G, Klugmann S, Bedogni F, Antoniucci D, Maisano F, Marzocchi A, Poli A, De Carlo M, Fiorina C, De Marco F, Napodano M, Violini R, Bortone AS, Tamburino C; Investigators CoreValve Italian Registry. Impact of coronary artery disease in elderly patients undergoing transcatheter aortic valve implantation: insight from the Italian CoreValve Registry. *Int J Cardiol.* 2013;167:943–950.
13. Paradis J, White JM, G en ereux P, Urena M, Doshi D, Nazif T, Hahn R, George I, Khaliq O, Harjai K, Lasalle L, Labb e BM, DeLarocheli ere R, Doyle D, Dumont E, Mohammadi S, Leon MB, Rod es-Cabau J, Kodali S. Impact of coronary artery disease severity assessed with the SYNTAX Score on outcomes following transcatheter aortic valve replacement. *J Am Heart Assoc.* 2017;6:e005070. DOI: 10.1161/JAHA.116.005070.
14. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW, Serruys PW. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. *EuroIntervention.* 2005;1:219–227.
15. Lumley M, Williams R, Asrress KN, Arri S, Briceo N, Ellis H, Rajani R, Siebes M, Piek JJ, Clapp B, Redwood SR, Marber MS, Chambers JB, Perera D. Coronary physiology during exercise and vasodilation in the healthy heart and in severe aortic stenosis. *J Am Coll Cardiol.* 2016;68:688–697.
16. Tu S, Xu L, Lighthart J, Xu B, Witberg K, Sun Z, Koning G, Reiber JH, Regar E. In vivo comparison of arterial lumen dimensions assessed by co-registered three-dimensional (3D) quantitative coronary angiography, intravascular ultrasound and optical coherence tomography. *Int J Cardiovasc Imaging.* 2012;28:1315–1327.
17. Ahn JH, Kim SM, Park SJ, Jeong DS, Woo MA, Jung SH, Lee SC, Park SW, Choe YH, Park PW, Oh JK. Coronary microvascular dysfunction as a mechanism of angina in severe AS: prospective adenosine-stress CMR study. *J Am Coll Cardiol.* 2016;67:1412–1422.
18. Sen S, Escaned J, Malik IS, Mikhail GW, Foale RA, Mila R, Tarkin J, Petraco R, Brody C, Jabbour R, Sethi A, Baker CS, Bellamy M, Al-Bustami M, Hackett D, Khan M, Lefroy D, Parker KH, Hughes AD, Francis DP, Di Mario C, Mayet J, Davies JE. Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis: results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) study. *J Am Coll Cardiol.* 2012;59:1392–1402.
19. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; Courage Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med.* 2007;356:1503–1516.
20. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, Pierpont G, Santilli S, Rapp J, Hattler B, Shunk K, Jaenicke C, Thottapurathu L, Ellis N, Reda DJ, Henderson WG. Coronary-artery revascularization before elective major vascular surgery. *N Engl J Med.* 2004;351:2795–2804.
21. Chakravarty T, Sharma R, Abramowitz Y, Kapadia S, Latib A, Jilaihawi H, Poddar KL, Giustino G, Ribeiro HB, Tchetchet D, Monteil B, Testa L, Tarantini G, Facchin M, Lefevre T, Lindman BR, Hariri B, Patel J, Takahashi N, Matar G, Mirocha J, Cheng W, Tuzcu ME, Sievert H, Rod es-Cabau J, Colombo A, Finkelstein A, Fajadet J, Makkar RR. Outcomes in patients with transcatheter aortic valve replacement and left main stenting: the TAVR-LM registry. *J Am Coll Cardiol.* 2016;67:951–960.

Key Words: Editorials • aortic stenosis • aortic valve implantation • coronary artery disease



Clinical Conundrum of Coronary Artery Disease and Aortic Valve Stenosis

Abdallah El Sabbagh and Rick A. Nishimura

J Am Heart Assoc. 2017;6:e005593; originally published February 20, 2017;

doi: 10.1161/JAHA.117.005593

The *Journal of the American Heart Association* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://jaha.ahajournals.org/content/6/2/e005593>

Subscriptions, Permissions, and Reprints: The *Journal of the American Heart Association* is an online only Open Access publication. Visit the Journal at <http://jaha.ahajournals.org> for more information.